MONJUVI
Peaktafasitamab-cxix
BLAINTRAVENOUSSOLUTIONPriority Review
Approved
Jul 2020
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
MONJUVI (tafasitamab-cxix) is tafasitamab-cxix is an fc-modified monoclonal antibody that binds to cd19 antigen expressed on the surface of pre-b and mature b lymphocytes and on several b-cell malignancies, including diffuse large b-cell lymphoma (dlbcl). First approved in 2020.
Drug data last refreshed 5h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MONJUVI (tafasitamab-cxix) is an Fc-modified CD19-directed monoclonal antibody approved for diffuse large B-cell lymphoma (DLBCL). It mediates B-cell lysis through apoptosis and immune effector mechanisms including ADCC and ADCP, with enhanced activity when combined with lenalidomide. This intravenous biologic represents a targeted immunotherapy approach to hematologic malignancy.
$0.001BPart D
PeakProduct is at peak lifecycle stage with modest Part D penetration; brand team will focus on market consolidation and indication expansion rather than launch activities.
Mechanism of Action
Tafasitamab-cxix is an Fc-modified monoclonal antibody that binds to CD19 antigen expressed on the surface of pre-B and mature B lymphocytes and on several B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL). Upon binding to CD19, tafasitamab-cxix mediates B-cell lysis through…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MONJUVI roles are concentrated in commercial, medical affairs, and market access functions typical of a peak-stage oncology biologic. Career opportunities emphasize payer negotiation, evidence generation, and field engagement rather than launch infrastructure.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.